阿尔茨海默病:当前和新兴的治疗方法
Runxuan Pang1, Qi Jia2, Chen Ma1
1The Conversationalist Club & Department of Dental Digitalization, School of Stomatology, Shandong First Medical University, Jinan, Shandong, China, sdfmu.edu.cn.
Behavioural neurology
|December 10, 2025
概括
本综述探讨了阿尔茨海默病 (AD) 的治疗方法,重点是针对粉样质斑块和神经纤维状结的药物. 它强调了植物提取物和新的基因疗法载体,以改善治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,由粉样β (Aβ) 斑块和神经纤维状结 (NFT) 标志着.
- 认知功能障碍是主要的症状,通常在病理变化开始后出现.
- 目前的AD治疗效果有限,需要针对核心病理的新型治疗方法.
研究的目的:
- 审查针对阿尔茨海默病 (AD) 的传统和新型药物,这些药物针对其关键的病理特征.
- 评估植物提取物在控制AD进展中的治疗潜力.
- 探索先进的药物输送系统,包括病毒载体和纳米粒子,用于基因疗法和向治疗.
主要方法:
- 对现有和新兴的AD疗法进行全面的文献综述.
- 对具有潜在抗AD活性的植物性化合物研究的分析.
- 检查对病毒载体和纳米颗粒用于AD治疗中药物输送的研究.
主要成果:
- 传统药物在AD进展方面提供了一些延迟,但针对Aβ斑块和NFTs的新型药物显示出有前途.
- 某些植物提取物在临床前研究中显示出缓解AD病理的巨大潜力.
- 基因疗法和基于纳米粒子的药物输送系统为增强AD治疗疗效提供了创新的策略.
结论:
- 迫切需要新的治疗方法,以阿尔茨海默病 (AD) 的潜在病理为目标.
- 植物提取物和先进的基因/药物输送系统为开发更有效的AD疗法提供了有希望的途径.
- 本综述提供了对阿尔茨海默病 (AD) 新型治疗机制和药物开发的见解.
相关概念视频
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
512
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
512
Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940


